JP Morgan Chase’s Acadia Pharmaceuticals ACAD Stock Holding History

JP Morgan Chase’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,000	Closed	-$415K	–	7362
2024 Q3	$415K	Hold	27,000	–	–	﹤0.01%	5022
2024 Q2	$439K	Buy	27,000 +19,300	+251%	+$311K	﹤0.01%	4760
2024 Q1	$142K	Buy	+7,700	New	+$191K	﹤0.01%	5518
2023 Q4	–	Sell	-192,000	Closed	-$4M	–	7483
2023 Q3	$4M	Buy	+192,000	New	+$5.21M	﹤0.01%	2997
2022 Q3	–	Sell	-102,700	Closed	-$1.45M	–	6418
2022 Q2	$1.45M	Buy	+102,700	New	+$1.92M	﹤0.01%	3818
2021 Q2	–	Sell	-10,500	Closed	-$271K	–	6304
2021 Q1	$271K	Hold	10,500	–	–	﹤0.01%	5020
2020 Q4	$561K	Buy	+10,500	New	+$521K	﹤0.01%	4304
2020 Q1	–	Sell	-74,100	Closed	-$3.17M	–	5240
2019 Q4	$3.17M	Buy	+74,100	New	+$3.22M	﹤0.01%	3048

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase's ACAD Position: Q2 2026 in Review

JP Morgan Chase reduced its Acadia Pharmaceuticals (ACAD) stake by 11% in Q2 2026, selling an estimated $625K and leaving 234,706 shares worth $6.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3281.

JP Morgan Chase first reported a position in ACAD in Q2 2013 and has held it in 53 quarters since. The position peaked at $72.1M in Q3 2017. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

JP Morgan Chase held 234,706 shares of Acadia Pharmaceuticals worth $6.06M as of Q2 2026.
JP Morgan Chase sold 28,385 Acadia Pharmaceuticals shares in Q2 2026, an estimated $625K.
Acadia Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3281 holding.
JP Morgan Chase first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
JP Morgan Chase's Acadia Pharmaceuticals position peaked at $72.1M in Q3 2017.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.